Downstream Effects of IL-23 Inhibition in Psoriasis

Downstream effects of IL-23 blockade in psoriasis

I'll pull up research on the downstream immunological and cellular effects of IL-23 blockade in psoriasis — cytokine cascades, T cell subsets, tissue changes, and the like.

The primary cytokine cascade

IL-23 (produced mainly by dermal dendritic cells and, notably, keratinocytes themselves in lesional skin) drives Th17 differentiation and maintains tissue-resident Th17 cells. Its downstream effectors — IL-17A, IL-17F, IL-22, and to a lesser extent IL-21 — then act on keratinocytes to drive hyperproliferation, antimicrobial peptide production (DEFB4A/B, S100A8), and inflammatory chemokine release. When you block IL-23, all of these cytokines should fall simultaneously, which is one claimed advantage over blocking IL-17A alone. The ECLIPSE substudy (guselkumab vs. secukinumab) directly tested this: guselkumab produced significantly greater reductions in serum IL-17F and IL-22 than secukinumab at weeks 24 and 48, with broader suppression of chemokine and TNF-pathway proteins in proteomic profiling of skin biopsies. The implication is that IL-23 blockade dampens the whole upstream regulatory program, while IL-17A blockade leaves IL-17F- and IL-22-driven inflammation partially intact.

Selective depletion of pathogenic T17 subsets

A single-cell RNA-seq study of 93 human psoriasis skin libraries found six distinct T17 subsets in psoriatic skin. Critically, only two of them — an IL-17A+IFN-γ+ subset and an IL-17F+IL-10− subset — express the IL-23 receptor, and these IL-23R+ subsets were selectively downregulated after risankizumab treatment. A third subset expressing both IL-17A and IL-17F but lacking IL-23R was not reduced and even increased proportionally, which may reflect its non-pathogenic role in barrier defense. The same study found that negative regulation of IL-17 signaling (via TNFAIP3 in myeloid cells) was enhanced more by IL-23 blockade than by IL-17A blockade — pointing to a more durable upstream reprogramming rather than just cytokine neutralization.

Regulatory T cell dynamics

In the psoriatic inflammatory environment, IL-23 drives Treg plasticity — pushing Foxp3+ cells to co-express RORγt and produce IL-17A, effectively converting them from suppressive to pathogenic. Removing the IL-23 signal reverses this. Anti-IL-23p19 antibody in imiquimod mouse models significantly expanded Foxp3+IL-10+ Tregs and restored their suppressive capacity, an effect that was not observed with anti-TNFα treatment. Guselkumab in human patients similarly increased circulating regulatory T cells and decreased tissue-resident memory T cells in a recent study.

Tissue-resident memory T cells and disease relapse

IL-23 is required for the in-skin proliferative maintenance of tissue-resident Th17 cells (Trm17). Anti-IL-23 therapy reduces Trm17 number and proliferation index in treated psoriasis skin — a mechanism that is thought to explain the unusually durable disease-free intervals observed with anti-IL-23 biologics after treatment withdrawal. A single-cell transcriptomic study added a wrinkle, however: IL-23 blockade reduced Th17/Tc17 cell frequency in lesional skin but failed to normalize an inflammation-suppressive transcriptional program that is sharply suppressed in lesional T cells. This residual transcriptional defect may explain why treated lesions remain primed for recurrence.

A critical caveat: persistent IL-17 via alternative pathways

Not all the downstream cytokines are reliably suppressed by IL-23 blockade. An analysis showed that while lesional IL-23 expression fell significantly, TNF-α, IL-17A, IL-22, and IL-36γ expression areas did not change. This suggests an IL-23-independent route of IL-17 production — possibly via γδ T cells, innate lymphoid cells, or Trm cells that no longer require IL-23 signaling — sustains the inflammatory loop in some patients. This is a genuinely important gap: the field doesn't yet have a reliable biomarker to predict who has significant IL-23-independent IL-17 production before starting a p19 inhibitor.

Keratinocyte-level effects

Blockading IL-23 upstream also reduces IL-36 expression in keratinocytes, apparently through a keratinocyte-autonomous IL-23/IL-36 loop that amplifies the inflammatory signal. Downstream of IL-17A on keratinocytes, ACT1-mediated activation of NF-κB and YAP-AREG signaling drives hyperproliferation; resolution of IL-17A levels after IL-23 blockade quiets these pathways as well.

Safety implications of upstream blockade

A notable practical consequence of targeting IL-23 rather than IL-17A directly is that IL-23 blockade largely preserves anti-Candida Th17 immunity. IL-17A is critical for mucocutaneous antifungal defense, and IL-17 inhibitors carry a clear class-associated Candida risk. IL-23 p19-specific inhibitors spare the IL-23-independent pool of IL-17-producing cells, which is consistent with the lower Candida infection rates observed in IL-23 inhibitor trials. This immunological advantage is one of the cleaner success stories of upstream targeting in this axis.

Taken together, the picture from this search is that IL-23 blockade does more than just reduce IL-17A: it selectively prunes the IL-23R-expressing pathogenic T17 subsets, restores Treg balance, depletes tissue-resident memory Th17 cells (the likely mediator of durable remission), and broadly suppresses the downstream cytokine program more completely than direct IL-17A blockade. The main unresolved question is what sustains IL-17 production in non-responders and after eventual relapse, given that some patients have IL-23-independent IL-17 sources that are not captured by current clinical biomarkers.